Provided by Tiger Trade Technology Pte. Ltd.

Phio Pharmaceuticals

1.21
-0.0850-6.59%
Volume:1.39M
Turnover:1.70M
Market Cap:12.97M
PE:-0.56
High:1.34
Open:1.28
Low:1.20
Close:1.29
52wk High:4.19
52wk Low:0.8127
Shares:10.76M
Float Shares:10.71M
Volume Ratio:0.25
T/O Rate:12.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1500
EPS(LYR):-9.0798
ROE:-107.58%
ROA:-60.16%
PB:1.32
PE(LYR):-0.13

Loading ...

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Benzinga_recent_news
·
1 hour ago

Phio Pharmaceuticals Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Benzinga_recent_news
·
Yesterday

Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results

TIPRANKS
·
Feb 10

Phio Pharmaceuticals- Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients)

THOMSON REUTERS
·
Feb 10

Phio Pharmaceuticals Corp - No Serious Adverse Events or Toxicities Identified Across All 5 Dose Escalation Cohorts - SEC Filing

THOMSON REUTERS
·
Feb 10

Phio Pharmaceuticals Corp - Complete Response (100% Tumor Clearance) in 4 of 6 Responders

THOMSON REUTERS
·
Feb 10

Phio Pharmaceuticals Corp - Announces Safety Review Conclusion for Ph-762 - SEC Filing

THOMSON REUTERS
·
Feb 10

Phio Pharmaceuticals meldet erfolgreiche Sicherheitsdaten für PH-762 in Phase-1b-Hautkrebsstudie

Reuters
·
Feb 10

Phio Pharmaceuticals to Present at DealFlow Discovery Conference in Atlantic City

Reuters
·
Jan 26

Buy Rating on Phio Pharmaceuticals: Early PH-762 Efficacy, Clean Safety Profile, and Solid Cash Runway Support Favorable Risk–Reward

TIPRANKS
·
Jan 21

Phio Pharmaceuticals Corp - Announces Key Tumor Response Data From Ph-762 Trial - SEC Filing

THOMSON REUTERS
·
Jan 20

Phio Pharmaceuticals Corp - Favorable Safety and Tolerability at All Dose Escalations - SEC Filing

THOMSON REUTERS
·
Jan 20

Phio Pharmaceuticals Corp: Safety Data Through Extended Follow-up Period Is Expected to Be Reported in Q2 of 2026

THOMSON REUTERS
·
Jan 20

Phio Pharmaceuticals Reports 70% Response Rate in PH-762 Skin Cancer Trial

Reuters
·
Jan 20

Phio Pharmaceuticals Showcases INTASYL siRNA Cancer Therapy at Sidoti Micro-Cap Virtual Investor Conference

Reuters
·
Jan 15

Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares

Reuters
·
Jan 03

Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares

Reuters
·
Dec 29, 2025

Phio Pharmaceuticals Corp - No Dose-Limiting Toxicities in Ph-762 Trial - SEC Filing

THOMSON REUTERS
·
Dec 23, 2025

Phio Pharmaceuticals Corp - Ph-762 Has Been Well Tolerated in All Enrolled Patients in Each Escalating Dose Cohort

THOMSON REUTERS
·
Dec 23, 2025